Oral Alternative To Injections
- SkinnyJab
- 2 days ago
- 2 min read
The main non-injection GLP-1 option is oral semaglutide (Rybelsus), a tablet that contains the same active ingredient as some injectable medications. Another non-injectable, non-peptide GLP-1 receptor agonist called orfoglipron has also been studied for weight reduction. While injectables like Ozempic® and Wegovy® are also semaglutide-based, Rybelsus provides a needle-free alternative for managing type 2 diabetes and for some individuals managing weight.
Key non-injectable GLP-1 medications:
This is the first oral GLP-1 receptor agonist, approved by the FDA for the management of type 2 diabetes. It works similarly to its injectable counterparts by stimulating insulin release, suppressing glucagon, and reducing appetite.
A non-peptide, oral GLP-1 receptor agonist developed for weight reduction in adults. Research in Phase 2 trials has shown it can lead to weight loss, and the side effects are similar to those of injectable GLP-1 agonists.
How to take Rybelsus:
Timing: You take it first thing in the morning on an empty stomach.
Dose: Swallow the tablet with a small sip of water.
Waiting Period: You must wait at least 30 minutes before eating, drinking, or taking other medications.
Benefits of non-injectable GLP-1 agonists:
No needles: Provides a needle-free alternative for people who are averse to injections.
Effective for specific conditions: Rybelsus is an effective option for managing type 2 diabetes.
Weight Management: Orforglipron and oral semaglutide can be effective options for weight reduction in suitable individuals.
Considerations:
Prescription: GLP-1 agonists are powerful medications and should only be taken under the guidance of a healthcare professional.
Side Effects: Common side effects can include nausea, vomiting, and diarrhea.
Different Formulations: While oral semaglutide (Rybelsus) is an oral form of semaglutide, it's distinct from the injectable forms like Ozempic® and Wegovy®.